The primary objective of this study is to examine whether exercise training alone, liraglutide treatment alone or exercise training plus liraglutide treatment increases cardiac and muscle capillary blood volume, improves vascular function in the larger conduit vessels, and enhances insulin's metabolic action in humans with Type 2 diabetes. Subjects will be randomized to one of the three groups: exercise training, liraglutide treatment, and exercise + liraglutide. They will be studied at the baseline and then after 16 weeks of intervention.
Age 21-60
A1C ≤ 8.5%
Never on GLP-1RA (eg: exenatide, liraglutide) or DPP4I ( eg: Sitaglipton)
On stable dose of oral hypoglycemic agents >4 months
Taking Insulin
Smoking presently or in the past 6 months
BP >160/90
BMI >35
Factorial
Exercise
Other intervention16 weeks of treatment
Liraglutide
Drug16 weeks of Liraglutide
Microvascular Blood Volume - change from baseline
measured at baseline and 16 weeks
Augmentation Index - change from baseline
measured at baseline and 16 weeks
Flow Mediated Dilation - change from baseline
measured at baseline and 16 weeks
Pulse Wave Velocity - change from baseline
measured at baseline and 16 weeks
Post Ischemic Flow Velocity-Change from baseline
measured at baseline and 16 weeks
Click on the lead sponsor to view all of their trials.
University of Virginia
Lead sponsor
American Diabetes Association
Collaborator
National Institutes of Health (NIH)
Collaborator
